• Posted on
Veliter at the 5th BIONNOVA

Veliter at the 5th BIONNOVA Biomedical Innovation Leaders Forum & Expo in Shanghai: Focus on Oligonucleotide API Quality Research, Process Development, and Large-scale Production​

Date: April 24th-25th, 2024

Location: Shanghai Zhangjiang Science Hall

Expo Theme: INNOVATION I PARTNERING I RE-IMAGINED

Veliter’s Presentation Topic: Quality Research, Process Development, and Large-scale Production of Oligonucleotide APIs

At the recent 5th BIONNOVA Biomedical Innovation Forum held at the Shanghai Zhangjiang Science Hall, Veliter, a leading expert in Oligo CDMO Solutions , delivered an insightful presentation on the current landscape and future prospects of oligonucleotide drugs.

  1. The Current State of Oligonucleotide Therapeutics: Veliter’s presentation began with an overview of the current status of oligonucleotide drugs in the pharmaceutical industry. 

  2. Advantages of Oligonucleotide Drugs: The presentation highlighted the numerous technological advantages of oligonucleotide drugs, including their potential for long-lasting effects, safety profiles, and ability to target previously undruggable pathways. These advantages position oligonucleotide drugs as the third major class of therapeutics, following small molecules and biologics, with the potential to benefit patients worldwide.

  3. Oligonucleotide Production at Veliter: Veliter showcased its expertise in oligonucleotide production, emphasizing its role as a leading provider of CRO/CDMO services in this field. With state-of-the-art facilities and a dedicated team of experts, Veliter is committed to advancing oligonucleotide therapies through quality research, efficient process development, and large-scale production capabilities.

  4. Collaboration and Investment Opportunities: The presentation concluded with an invitation to explore collaboration opportunities with Veliter. Whether through project partnerships or investment discussions, Veliter welcomes opportunities to advance the development and commercialization of oligonucleotide therapeutics.

In summary, Veliter’s presentation at the 5th BIONNOVA Biomedical Innovation Forum provided valuable insights into the evolving landscape of oligonucleotide therapeutics and highlighted the company’s commitment to driving innovation in this exciting field.